Handling competing interests

Decision of the Executive Director on transparency measures for senior staff leaving the Agency

Joint Committee Opinion 27/2020 on criteria and restrictions for senior staff applying for occupational activities within two years after leaving the Agency

Establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation

Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation application

Guidance for competent authorities on how to highlight VNRAs

Human medicines European public assessment report (EPAR): Suliqua, insulin glargine,lixisenatide, Date of authorisation: 11/01/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Kalydeco, ivacaftor, Date of authorisation: 23/07/2012, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Tecentriq, atezolizumab, Date of authorisation: 20/09/2017, Revision: 29, Status: Authorised

Translating innovation into access for ATMPs: 3rd EU-Innovation network multi-stakeholder meeting, Online, Rome, Italy, Broadcast, from 15 November 2024, 09:00 (CET) to 15 November 2024, 17:00 (CET)